Immunic Inc. Stock
Price
Target price
€0.80
€0.80
-5.920%
-0.049
-5.920%
€8.57
20.02.26 / Tradegate
WKN: A2PHD4 / Symbol: IMUX / Name: Immunic / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Immunic
sharewise wants to provide you with the best news and tools for Immunic, so we directly link to the best financial data sources.
Financials
News
EQS-News: Immunic Announces Closing of Oversubscribed Private Placement Financing
EQS-News: Immunic Announces Closing of Oversubscribed Private Placement Financing
EQS-News: Immunic Highlights 2025 Accomplishments and Upcoming Milestones
EQS-News: Immunic Highlights 2025 Accomplishments and Upcoming Milestones
EQS-News: Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
EQS-News: Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
EQS-News: Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
EQS-News: Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
EQS-News: Immunic to Participate in Industry and Investor Conferences in November
EQS-News: Immunic to Participate in Industry and Investor Conferences in November
EQS-News: Immunic to Participate in Scientific and Investor Conferences in October
EQS-News: Immunic to Participate in Scientific and Investor Conferences in October
EQS-News: Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
EQS-News: Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
EQS-News: Immunic to Participate in Investor and Scientific Conferences in September
EQS-News: Immunic to Participate in Investor and Scientific Conferences in September